Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERFECT: CD133+ Stem Cells + CABG
NCT00950274Phase 3Terminated
- Sponsor
- Miltenyi Biotec
- Start
- Jul 2009
- Primary completion
- Mar 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of autologous CD133+ cells in coronary artery disease (CAD), sponsored by Miltenyi Biotec. Started Jul 2009; status: terminated.
02
Drugs
autologous CD133+ cells
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00950274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00950274.